MEDICAL POLICY DETAILS

<table>
<thead>
<tr>
<th>Medical Policy Title</th>
<th>LIGHT AND LASER THERAPIES FOR DERMATOLOGIC CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>8.01.21</td>
</tr>
<tr>
<td>Category</td>
<td>Technology Assessment</td>
</tr>
<tr>
<td>Effective Date</td>
<td>09/21/06</td>
</tr>
<tr>
<td>Revised Date</td>
<td>09/20/07, 07/17/08, 09/17/09, 10/28/10, 09/15/11, 09/20/12, 09/19/13, 09/18/14, 09/17/15, 09/15/16, 09/21/17, 09/20/18, 08/15/19</td>
</tr>
</tbody>
</table>

Product Disclaimer

- If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
- If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.
- If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

POLICY STATEMENT

I. Based upon our criteria and review of peer-reviewed literature, the following have been medically proven to be effective, and therefore, are medically appropriate:

A. Ultraviolet B (UVB) light alone or in combination with other treatment modalities for the following indications:
   1. moderate to severe psoriasis, not responsive to topical or systemic (e.g. methotrexate) drug therapies alone;
   2. eczema/ atopic dermatitis, not responsive to topical or systemic drug therapies alone, or that interferes with an individual’s normal functional capacity;
   3. cutaneous T-cell lymphoma (e.g., mycosis fungoides); or
   4. vitiligo of sun exposed regions (such as the face, neck and dorsum of the hands) because the depigmented skin is sun sensitive, subject to severe sunburn and may pose a risk for skin cancer.

B. Psoralen Ultraviolet A (PUVA), for the following indications:
   1. severe, disabling psoriasis, not responsive to conservative therapy or UVB therapy;
   2. severe, disabling eczema/ atopic dermatitis, not responsive to conservative therapy or UVA/UVB therapy;
   3. cutaneous T-cell lymphoma (e.g., mycosis fungoides); or
   4. vitiligo of sun exposed regions (such as the face, neck and dorsum of the hands) because the depigmented skin is sun sensitive, subject to severe sunburn and may pose a risk for skin cancer.

C. Ultraviolet A (UVA) light alone or in combination with other treatment modalities for the treatment of eczema/ atopic dermatitis not responsive to topical or systemic drug therapies alone, or that interferes with an individual’s normal functional capacity.

D. Targeted phototherapy using a device with FDA 510k approval (e.g., XTRAC XL™ excimer laser and VTRAC™ excimer lamp system, BClear™ lamp, and European manufactured Excilite™ and Excilite µ™ XeCL lamps) for the following:
   1. treatment of moderate to severe localized psoriasis comprising less than 20% of the body area for which B-UVB or PUVA are indicated; or
   2. treatment of mild to moderate psoriasis that is unresponsive to conservative treatment

E. Home phototherapy utilizing UVB radiation for the treatment of moderate to severe psoriasis, comprising at least 3% of the body area, which is not responsive to conservative therapies or eczema/ atopic dermatitis which is not responsive to conservative therapies when all of the following criteria have been met:
1. letter of medical necessity from the dermatologist stating the reason the home-based rather than office-based therapy is needed;
2. the patient has had ineffective courses of treatment using topical or systemic drug therapy;
3. the patient must be motivated and reliable so that treatment is pursued correctly, consistently and exposures are accurately recorded.

F. Photodynamic Therapy (PDT) with 5-ALA or Metvix® topical preparations for the treatment of:
   1. non-hyperkeratotic actinic keratoses of the face and scalp;
   2. superficial basal cell skin cancer only when surgery and/or radiation is contraindicated; or
   3. Bowen’s disease (squamous cell carcinoma in situ) only when surgery and/or radiation is contraindicated.

II. Based upon our criteria and review of peer-reviewed literature, the following have not been medically proven effective, and therefore, are considered investigational:
   A. Targeted phototherapy (e.g., the XTRAC XL™ and VTRAC™ lamp, the BClear™ lamp, and the European manufactured Excilite™ and Excilite µ™ XeCL lamps) for the following indications:
      1. first-line treatment of mild psoriasis; and
      2. treatment of generalized psoriasis or psoriatic arthritis; and
      3. vitiligo.
   B. PDT with topical preparations for the treatment of other dermatologic conditions including, but not limited to acne vulgaris, squamous cell carcinoma, and non-superficial basal cell carcinoma.
   C. Treatment of acne with light or laser therapy; including pulsed dye or smooth beam laser.

III. Contraindications:
   A. The following are contraindications of phototherapy and PUVA:
      1. Xeroderma pigmentosum,
      2. Disorders with significant light sensitivity (e.g., albinism), and
      3. Lupus erythematosus.
   B. The following are contraindicated for PUVA, but phototherapy may be used:
      1. Breast-feeding,
      2. Pregnancy, and
      3. Uremia and hepatic failure.
   C. Treatment should be used with caution in the following circumstances:
      1. History or family history of melanoma,
      2. Past history of non-melanoma skin cancer, extensive solar damage, and previous treatment with ionizing arsenic,
      3. Pemphigus or pemphigoid,
      4. Immunosuppression,
POLICY GUIDELINES

I. The number of treatments required for clearance and remission for both UVB and PUVA therapy is based upon severity of the disease and the individual response to treatment. The number of psoriatic flare-ups a person experiences in a lifetime also varies by severity of the disease.

II. UVB therapy usually begins with 3 to 5 sessions per week until clearing is achieved followed by maintenance therapy with a gradual reduction in sessions until none are required. PUVA therapy begins with 2 to 3 sessions per week for initial clearing then 1 to 2 times a month for maintenance. If no improvement in the psoriatic lesions is seen after 4 weeks of either UVB or PUVA therapy, treatment should be discontinued.

III. Any requests for medical necessity documentation, such as a treatment plan and/or photographs, are generally not required until after a threshold of 30 visits.

IV. The number of treatments required for clearance and remission for atopic dermatitis/eczema and for repigmentation in vitiligo for both UVB a PUVA Therapy is based upon severity of the disease and the individual response to treatment.

V. In general, a phototherapy home unit should be purchased only when there is anticipation of long-term use.

VI. Because of its potential long-term side effects PUVA is rarely indicated for children or young adults.

VII. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION

Ultraviolet light therapy is exposure to the skin with non-ionizing radiation for therapeutic benefit. It may involve exposure to ultraviolet B (UVB), ultraviolet A (UVA) or various combinations of UVB and UVA radiation.

Excimer laser, a xenon chloride (XeCl) laser (e.g., XTRAC, Ex-308 laser), emits a narrow beam of UVB light from a handheld unit which results in a much higher concentration of UVB exposure than in the standard phototherapy unit. The use of excimer laser may shorten the number of exposures necessary, and only specific areas of the body are treated with the laser; limiting the number of exposures and the area being treated can reduce the harmful effects of UV radiation.

Photochemotherapy is the therapeutic use of radiation in combination with a photosensitizing chemical, currently Psoralens and UVA radiation (PUVA). Psoralens makes the skin more sensitive and responsive to this wavelength of light. It can be taken orally, applied topically or patients can soak in a bath of Psoralens solution.

Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) has been investigated as a treatment of actinic keratoses (AK), skin cancers and superficial dermatologic lesions such as Bowen’s disease. Levulan® Kerastick® is one example of a topical preparation of 5-ALA. The Levulan® Photodynamic system is a 2-step treatment, involving
application of Levulan® Kerastick® then exposure of the area to blue light via the BLU-U® Blue Light Photodynamic Therapy Illuminator.

Topical application of methyl aminolevulinate (Metvix®, MAL) followed by exposure with the CureLight Broadband (Model CureLight 01), a proprietary red light source, or the PhotoCure Aktilite CL128 lamp, a LED based narrow band (630 nm) red light technology device, is another variant of photodynamic therapy for skin lesions.

The use of photodynamic therapy via the BLU-U® Blue Light Photodynamic Therapy Illuminator and intense pulsed light have been investigated for the treatment of acne vulgaris, and has received FDA approval for this indication.

Psoriasis disease severity is minimally defined by body surface area lesion characteristics (e.g., location and severity of erythema, scaling, induration, and pruritus) and impact on quality of life are also taken into account. For example, while one handprint is equal to approximately 1% body surface area, lesions on the hands, feet, or genitalia that cause disability may be classified as moderate to severe. Mild psoriasis affects less than 5% of the body’s surface area, moderate psoriasis affects 5% to 10%, and severe disease affects more than 10% body surface area.

**RATIONALE**

The published data has demonstrated that psoriasis has an excellent response rate when treated with either UVB or PUVA. The overall risk of complications from phototherapy and photochemotherapy are low when compared to the thousands of patients treated with these therapies. Phototherapy and photochemotherapy have been standard treatment alternatives used by dermatologists for severe psoriasis and for vitiligo.

National Institute for Health and Care Excellence (NICE) updated their Clinical Guideline for Psoriasis: Assessment and Management in 2017. The guidelines suggest offering narrowband ultraviolet B (UVB) phototherapy to people with plaque or guttate-pattern psoriasis that cannot be controlled with topical treatments alone, to consider psoralen (oral or topical) with local ultraviolet A (PUVA) irradiation to treat palmoplantar pustulosis, and when considering PUVA for psoriasis (plaque type or localized palmoplantar pustulosis) discuss other treatment options and associated risk of increased skin cancer.

The National Psoriasis Foundation defines the classifications of psoriasis as; Mild < 3%; Moderate 3-10% and Severe >10%. However, the severity of psoriasis is also measured by how psoriasis affects a person's quality of life. For example, psoriasis can have a serious impact on one's daily activities even if it involves a small area, such as the palms of the hands or soles of the feet.

Published data have demonstrated that phototherapy in the form of UVA, UVB and PUVA have been proven to be safe and effective treatments with a low overall risk of complications, for eczema/atopic dermatitis. The American Academy of Dermatology Association lists phototherapy and photochemotherapy as treatments for eczema in its most recently published Guidelines of Care for Phototherapy and Photochemotherapy, and Guidelines of Care for Atopic Dermatitis. The peer-reviewed literature consists of small case series that indicate good outcomes when phototherapy in the form of PUVA and UVB is used for the treatment of mycosis fungoides, a very rare lymphoma of the skin.

PhotoMedex (XTRAC laser) and Surgilight (EX-308 laser) have received FDA 510(k) market approval for the use of excimer lasers in the treatment of psoriasis. 510(k) clearance has subsequently been obtained for a number of targeted UVB lamps and lasers, including the XTRAC XL™ laser and VTRAC™ lamp (PhotoMedex), the BClear™ lamp (Lumenis), and the European manufactured Excilite™ and Excilite µ™ XeCL lamps. The indicated use of these devices is targeted UVB phototherapy for treatment of skin conditions including psoriasis, vitiligo, atopic dermatitis, and leukoderma. Peer-reviewed literature is limited; however, the published evidence supports the use of targeted phototherapy for the treatment of moderate to severe psoriasis comprising less than 20% body area for which NB-UVB or PUVA are indicated, and for the treatment of mild to moderate psoriasis that is unresponsive to conservative treatment. There is insufficient evidence to support the use of targeted phototherapy for the first-line treatment of mild psoriasis or for the treatment of generalized psoriasis or psoriatic arthritis.
A 2016 systematic review identified 3 studies that compared targeted phototherapy with a 308 nm excimer lamp to NB-UVB and 3 studies that compared the excimer lamp to the excimer laser. No differences between the excimer lamp and NB-UVB were identified for the outcome of 50% or greater repigmentation (RR=1.14; 95% CI, 0.88 to 1.48). For repigmentation of 75% or greater, only 2 small studies were identified and the relative risk was 1.81 (95% CI, 0.11 to 29.52), showing a lack of precision in the estimate. For the 3 studies that compared the excimer lamp to the excimer laser, there were no significant differences between treatments for either 50% or greater repigmentation (RR=0.97; 95% CI, 0.84 to 1.11) or 75% or greater repigmentation (RR=0.96; 95% CI, 0.71 to 1.30). All treatments were most effective in lesions located on the face, with the worst response being lesions on the extremities. There was some evidence of an increase in adverse events such as blistering with targeted phototherapy.

A recent Cochrane review update addressing interventions for vitiligo included the review of 12 trials on laser light devices. Six trials evaluated the combination of laser light devices and a topical therapy and 2 evaluated the combination of laser devices and surgical therapy. Three trials compared regimens of laser monotherapy. The remaining trial compared a helium neon laser and a 290 to 320 nm broadband ultraviolet B (UVB) fluorescent lamp. Due to heterogeneity across studies, the authors did not pool study findings. In most trials, all groups received laser light treatment, alone or as part of combination therapy; making the efficacy of targeted phototherapy unable to be determined. (Whitton, et al; 2015).

Bae, JM, et al. (2017) performed a systematic review and meta-analysis of patient response to narrowband UV-B (NB-UVB) phototherapy and psoralen-UV-A (PUVA) phototherapy in the treatment of vitiligo. Inclusion criteria consisted of: 1) prospective studies, 2) participants with a diagnosis of generalized or symmetrical vitiligo, 3) at least 1 phototherapy group, 4) at least 10 participants in each treatment arm, 5) treatment duration of at least 12 weeks or 24 treatment sessions, 6) outcomes measured based on all vitiligo lesions on the participants whole or half body, and 7) degree of repigmentation based on a quartile scale. In the final analysis, 35 studies were included with 29 studies of 1201 patients undergoing NB-UVB phototherapy and 9 studies of 227 patients undergoing PUVA phototherapy. A mild response (≥25%) to NB-UVB phototherapy occurred in 62.1% of 130 patients in 3 studies at 3 months, 74.2% of 232 patients in 11 studies at 6 months, and 75.0% of 512 patients in 8 studies at 12 months. A marked response defined as ≥75% was achieved in 13.0% of 106 patients in 2 studies at 3 months, 19.2% of 266 patients in 13 studies at 6 months, and 35.7% of 540 patients in 9 studies at 12 months. For PUVA phototherapy, at least a mild response occurred in 51.4% of 103 patients in 4 studies at 6 months and 61.6% of 72 patients in 3 studies at 12 months. After at least 6 months of NB-UVB phototherapy, at least a mild response occurred on the face and neck in 82.0% of 153 patients and a marked response in 44.2%, while hands and feet received a mild response in 11.0% of 172 patients and no marked responses of the same group. The authors could not determine the appropriate treatment duration of phototherapy but did verify treatment duration of at least 1 year to achieve maximal response and suggested at least 6 months of treatment to determine responsiveness to NB-UVB phototherapy. Overall, treatment response to NB-UVB phototherapy was better than PUVA therapy. The most responsive body site was the face and neck with hands and feet being the least responsive.

A 2015 systematic review of RCTs that focused on treatment of vitiligo with the 308 nm excimer laser. Authors identified 7 RCTs with a total of 390 patients. None of the studies were conducted in the United States. Three of the trials compared the excimer laser with an excimer lamp. Four studies compared the excimer laser with narrowband (NB)-UVB; however, 2 of these were not published in English and 1 had a sample size of only 14 patients. The fourth study, published in 2010, did not report efficacy outcomes such as clinical response rate or repigmentation rate; but reported on the proportion of patients with various types of repigmentation: perifollicular, marginal, diffuse, or combined. Repigmentation rates did not differ significantly between groups treated with the excimer laser versus NB-UVB. The authors conducted a meta-analysis of the 2 studies that were not published in English, so results cannot be verified, but they reported that the likelihood of a minimum 50% repigmentation rate was significantly higher with the excimer laser compared with NB-UVB (risk ratio, 1.39, 95% confidence interval [CI], 1.05 to 1.85) and that, in qualitative analysis, neither of these studies showed significant benefit of the excimer laser for achieving a minimum 75% repigmentation rate. (Sun, et al, 2015).

Studies addressing targeted phototherapy for treating vitiligo tend to have small sample sizes, few were designed to isolate the effect of laser therapy, were heterogeneous (e.g., different interventions or combinations of interventions, and different comparison interventions) which make it difficult to pool study findings or to draw conclusions about the efficacy of targeted phototherapy for vitiligo.
The use of PDT with 5-ALA is FDA approved only for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp. The use of PDT with Metvix® (US trade name Metvixia™) is FDA approved only for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients. However, off-label uses such as the treatment of basal cell carcinoma, photoaging, and acne vulgaris are common. Studies demonstrate that photodynamic therapy with 5-ALA or Metvix® is an effective nonsurgical technique of treating non-hyperkeratotic actinic keratoses (AK) of the face and scalp with an acceptable rate of recurrence over 12 months of 19%.

In 2007, the International Society for Photodynamic Therapy in Dermatology published consensus-based guidelines on the use of PDT for nonmelanoma skin cancer. Based on efficacy and cosmetic outcome, the authors recommended PDT as a first-line therapy for actinic keratosis. The guideline recommended PDT for superficial basal cell carcinoma as “a viable alternative when surgery would be inappropriate or the patient or physician wishes to maintain normal skin appearance and concludes that PDT is at least as effective as cryotherapy or 5-FU for Bowen’s disease. The authors found insufficient evidence to support the routine use of topical PDT for squamous cell carcinoma. (Braathen LR, et al.)

The 2017 Clinical Practice Guidelines in Oncology from the National Comprehensive Cancer Network state that in patients with low-risk, superficial basal cell cancer or low-risk squamous cell carcinoma in situ (Bowen’s disease) where surgery or radiation is contraindicated or impractical, topical therapies such as 5-fluorourcil, imiquimod, photodynamic therapy (e.g., aminolevulinic acid [ALA], porfimer sodium), or vigorous cryotherapy may be considered, even though the cure rate may be lower.

Overall, the literature investigating the use of PDT in the treatment of acne consists of very small studies in which the patient serves as their own control. These studies lack long-term data on effectiveness and safety.

Due to the small sample sizes of the published trials, lack of long-term follow-up, small number of studies on any particular type of laser, and paucity of studies comparing light therapy to standard acne treatments, the evidence is insufficient to draw conclusions about the impact of laser treatments on health outcomes in patients with active acne.

**CODES**

- Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>96567</td>
<td>Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitive drug per day</td>
</tr>
<tr>
<td>96573</td>
<td>Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day – (effective 01/01/18)</td>
</tr>
<tr>
<td>96574</td>
<td>Debridement of premalignant hyperkeratotic lesion(s) (ie, targeted curettage, abrasion) followed with photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day – (effective 01/01/18)</td>
</tr>
<tr>
<td>96900</td>
<td>Actinotherapy (ultraviolet light)</td>
</tr>
</tbody>
</table>
## Code | Description
---|---
96910 | Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B
96912 | Psoralens and ultraviolet A (PUVA)
96913 | Photochemotherapy (Goeckerman and/or PUVA) for severe photosensitive dermatoses requiring at least four to eight hours of care under direct supervision of the physician (includes application of medication and dressings)
96920 | Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm
96921 | 250 sq cm to 500 sq cm
96922 | Over 500 sq cm

---

### HCPCS Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E0691</td>
<td>Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; treatment area two square feet or less</td>
</tr>
<tr>
<td>E0692</td>
<td>Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, four foot panel</td>
</tr>
<tr>
<td>E0693</td>
<td>Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, six foot panel</td>
</tr>
<tr>
<td>E0694</td>
<td>Ultraviolet multidirectional light therapy system in six foot cabinet, includes bulbs/lamps, timer and eye protection</td>
</tr>
<tr>
<td>J7308</td>
<td>Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg)</td>
</tr>
<tr>
<td>J7309</td>
<td>Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram</td>
</tr>
</tbody>
</table>

### ICD10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C44.00-C44.99</td>
<td>Other and unspecified malignant neoplasm of skin (code range)</td>
</tr>
<tr>
<td>C80.0-C80.2</td>
<td>Malignant neoplasm without specification of site (code range)</td>
</tr>
<tr>
<td>C84.00-C84.09</td>
<td>Mycosis fungoides; code range</td>
</tr>
<tr>
<td>C84.10-C84.19</td>
<td>Sézary disease; code range</td>
</tr>
<tr>
<td>D04.0-D04.9</td>
<td>Carcinoma in situ of skin (code range)</td>
</tr>
<tr>
<td>L40.0-L40.9</td>
<td>Psoriasis (code range)</td>
</tr>
<tr>
<td>L57.0</td>
<td>Actinic keratosis</td>
</tr>
<tr>
<td>L70.0-L70.9 (E/I)</td>
<td>Acne (code range)</td>
</tr>
<tr>
<td>L73.0 (E/I)</td>
<td>Acne keloid</td>
</tr>
<tr>
<td>L80</td>
<td>Vitiligo</td>
</tr>
</tbody>
</table>
REFERENCES


*Key Article
KEY WORDS

Aminolevulinic acid, BClear lamp, Excilite lamp, Levulan® Kerastick®, methyl aminolevulinate, Metvix®, Narrow band ultraviolet B, Psoralens, PUVA, Ultraviolet light, UVA, UVB, xenon chloride laser, XeCL, XTRAC, VTRAC lamp.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD) for the Treatment of Psoriasis and an NCD for the Treatment of Actinic Keratosis. Please refer to the following websites for Medicare Members:

https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=88&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Upstate&KeyWord=psoriasis&KeyWordLookUp=Title&KeyWordSearchType=And&ncd_id=250.1&ncd_version=1&basket=ncd%25253A250%25252E1%252525A1%252525A1Treatment+of+Psoriasis&bc=gAAAAABAAAAA&

https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=129&ncdver=1&NCAId=1&ver=23&NcaName=Actinic+Keratoses&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Upstate&KeyWord=actinic+keratoses&KeyWordLookUp=Title&KeyWordLookUp=Title&KeyWordSearchType=And&KeyWordSearchType=And&ncd_id=250.1&ncd_version=1&basket=ncd%25253A250%25252E1%252525A1%252525A1Treatment+of+Psoriasis&bc=gAAAAABAAIAAA&